![logo](/logos/IMRX.webp)
Immuneering Corporation
NASDAQ:IMRX
1.18 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Immuneering Corporation |
Symbool | IMRX |
Munteenheid | USD |
Prijs | 1.18 |
Beurswaarde | 34,991,012 |
Dividendpercentage | 0% |
52-weken bereik | 1 - 9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. |
Website | https://immuneering.com |
An error occurred while fetching data.
Over Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)